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Background: The obesity hormone, leptin, has been found to play a role in development and proliferation of normal
and malignant tissues. Leptin activity is mediated through the leptin receptor (ObR) that is often expressed in
different human cancer cells. Previously, we found that the expression of leptin and ObR can be stimulated by
hypoxia-mimetic agents. The aim of this study was to analyze the abundance of and relationships among leptin, ObR
and hypoxia-inducible factor-1a (HIF-1a, transcriptional regulator) in human colorectal cancer.
Materials and methods: We investigated the expression of leptin, ObR and HIF-1a in colorectal cancer specimens
from 135 patients who underwent curative resection.
Results: Immunoreactivity for leptin, ObR and HIF-1a protein was observed in 69 of 135 (51.1%), 129 of 135 (95.5%)
and 88 of 135 (65.2%) of colorectal cancers, respectively.
Statistically significant positive correlations were noted between leptin and HIF-1a (P = 0.005, r = 0.243), ObR
and HIF-1a (P < 0.001, r = 0.325) as well as leptin and ObR (P < 0.001, r = 0.426) in the group of all patients as
well as in various subgroups depending on clinicopathological features.
Conclusions: The results indicate that the leptin system is overexpressed in human colorectal cancer and this
overexpression appears to be associated with the abundance of HIF-1a.
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introduction
Leptin (obesity protein) is a 16 kDa cytokine produced
mainly by adipose tissue. The levels of circulating leptin in
humans are proportional to body mass index and are
significantly elevated in obese individuals [1]. Leptin has
been first described as a hormone regulating energy balance
in the brain. In addition, leptin is known to influence various
reproductive and immune processes in peripheral organs
[2, 3]. Later studies documented that the hormone can also
influence malignant progression [4–7]. Numerous studies
demonstrated that different tumor tissues and cell lines
respond to leptin and express functional leptin receptors
(ObRs) [6–12]. Importantly, in breast, endometrial and
gastric cancers, the expression of ObR has been found
significantly elevated relative to noncancer control cases
[8–13] The activation of ObR and subsequent induction of
multiple signaling cascades, such as the JAK2/STAT3, ERK1/2,
PKC-alpha and Akt/GSK3 pathways, has been shown to
stimulate cell growth, transformation and survival [7–16].
Leptin can also promote invasiveness, migration and
neoangiogenesis, all of which can promote tumor spreading
[17–19]. Interestingly, we and others observed that different
cancer tissues (e.g. breast, endometrial) coexpress leptin
and ObR [8–20], indicating that leptin might affect tumor cells
in an autocrine manner. The mechanism of this concomitant
overexpression is not clear, but our data obtained in breast
cancer cell lines indicate the involvement of obesity-related
stimuli, including development of hypoxic conditions [8].
Hypoxia is a characteristic feature of cancers, especially
fast developing tumors, and can also be induced by excess of
surrounding adipose tissue. Lack of proper oxygenation
stimulates the expression of various genes, e.g. those
encoding for glycolytic enzymes, growth factors, their
receptors and vasoactive peptides [21, 22]. The expression
of numerous hypoxia-responsive genes is regulated by
hypoxia-inducible factor-1 (HIF-1). HIF-1 is a basic
helix–loop–helix transcription factor of heterodimeric
structure that contains constitutively expressed HIF-1b and
hypoxia-induced HIF-1a subunits [23]. HIF-1a activates













*Correspondence to: Dr S. Sulkowski, Department of Pathomorphology,
Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland.
Tel: +48-85-7485944; Fax: +48-85-7485944; E-mail: sulek@zeus.amb.edu.pl
ª 2007 European Society for Medical Oncology
element (HRE) present in promoter region of target genes
[24]. Noteworthy, the leptin gene promoter contains eight
HRE with the minimal core sequence 5#-RCGTG-3 that can
recruit HIF-1. The leptin promoter has been shown to be
induced by hypoxia or hypoxia-mimetic agents in BeWo cells
[25, 26]. Our preliminary data indicate that similar mechanism
might operate in breast cancer cells (S. Cascio, V. Bartella,
A. Auriemma et al., unpublished data).
Obesity is one of the risk factors for colon cancer, and some
preliminary reports indicate that leptin may enhance colorectal
cancer cell growth. For instance, coculture of colorectal
cancer cells with leptin-producing adipocytes significantly
increased proliferation of cancer cells [27]. Other data obtained
with cellular models indicated that in colorectal cancer cells
(HT-29, LoVo, Caco2, SW 480 and HCT-8/S11 lines) leptin
can activate the Mitogen-Activated Protein Kinase (MAPK)
and Phosphoinositide-3 kinase (PI-3K) pathways and stimulate
DNA synthesis, cell proliferation, migration and invasion [7–
29]. It is possible that leptin impacts on the development and
progression of human colorectal cancer, as we noticed
significant overexpression of the hormone in colorectal
cancer tissues [30]. However, the expression of ObR and
HIF-1a colorectal cancer biopsies has never been described.
Consequently, here we investigated the abundance of the
leptin system and HIF-1a in human colorectal cancer and
we assessed correlations among these biomarkers.
methods and results
immunohistochemistry
The study included specimens of primary colorectal cancers from
135 patients who underwent curative resection. The age of patients ranged
from 35 to 92 years (mean 65.8 years). Tumor samples were collected
immediately after tumor removal, fixed in 10% buffered formaldehyde
solution for 48 h, embedded in paraffin blocks at 56oC according to
standard procedures and then stained with hematoxylin and eosin.
Leptin, ObR and HIF-1a were investigated in representative tissue
sections using specific antibodies (Abs): for leptin, polyclonal Ab (pAb)
A-20 (Santa Cruz Biotechnology, Santa Cruz, CA); for ObR, pAb H-300
(Santa Cruz Biotechnology); for HIF-1a, pAb (Santa Cruz Biotechnology).
All primary Abs were diluted in phosphate-buffered saline with
1.5% normal blocking serum. Immunohistochemistry was carried out as
described previously [8]. Ab–antigen reaction was revealed with
avidin–biotin–peroxidase complex (ABC Staining System) for leptin,
and EnVision system for ObR and HIF-1a, and then the slides were
counterstained with hematoxylin. In negative controls, primary Abs
were omitted. The immunostaining for leptin, ObR and HIF-1a was
analyzed in 10 different tumor fields and the mean percentage of tumor
cells with positive staining was calculated. The expression of studied
proteins was classified using a three-point scale: 0, <10% positive cells; 1+,
10%–50% positive cells; 2+, >50% cells with positive staining.
statistics
The associations among leptin, ObR and HIF-1a were determined using
Spearmans correlation analysis. Probabilities of P < 0.05 were taken as
statistically significant.
leptin and ObR are frequently expressed in human
colorectal cancer
The study included colorectal cancers classified histopathologically as
adenocarcinoma (117 cases) and adenocarcinoma mucinosum (18 cases);
95 cases in G2 grade and 40 cases in G3 grade. For statistical analyses,
because of both clinical staging and relatively small number of pT1, pT2
and pT4 cases, the samples were divided into two groups, pT1 plus pT2
(14 cases) and pT3 plus pT4 (121 cases). In all, 68 of 135 (50.4%)
patients had involved lymph nodes at the time of diagnosis.
Positive leptin, ObR and HIF-1a immunostaining were detected in
69 of 135 (51.1%), 129 of 135 (95.5%) and 88 of 135 (65.2%), respectively.
Immunohistochemical analysis of colorectal cancer sections revealed
cytoplasmatic localization and microgranular staining for leptin and
cytoplasmatic/membrane as well as occasionally nuclear staining for ObR.
HIF-1a staining exhibited mainly granular cytoplasmatic pattern, with
perinuclear concentration; in some cases nuclear HIF-1a
immunoreactivities were noted. The expression of studied proteins was
undetectable in the control samples when immunostaining was carried
out with the omission of primary Abs.
expression of the leptin system correlates with HIF-1a
We found a positive correlation between leptin and ObR (for the group
of all patients: P < 0.001, r = 0.426), except for poorly differentiated
tumors, subgroups of mucinous cancers and tumors in pT1 + pT2 stage
(Table 1). Statistically significant positive correlation between leptin
and HIF-1a was noted in the group of all patients (P = 0.005, r = 0.243),
and in various subgroups as follows: sets of patients with lymph node
involvement, more advanced tumors (pT3 + pT4), moderately
differentiated (G2) tumors, adenocarcinoma type of tumors, subgroup
of women, older patients and in tumors located in rectum (Table 1).
We also found statistically significant linkage of ObR and HIF-1a
in the group of all patients (P < 0.001, r = 0.325) and some subgroups
characterized by various clinicopathological features, except for poorly
differentiated tumors, subgroups of mucinous cancers and tumors
located in the rectum (Table 1).
discussion
Recent data indicated that leptin system might be involved in
development and progression of various human malignancies
[4–13]. For instance, we observed abundant expression of
leptin and ObR in primary and metastatic breast cancer and
in endometrial cancer tissue. In these studies, the leptin/ObR
system was overexpressed in cancer relative to non-tumor
tissues [8–13]. Ishikawa et al. [31] indicated that
coexpression of leptin and ObR could play a role in gastric
cancer progression via auto- and paracrine mechanisms.
Despite some indications from cellular models, the impact
of the leptin system on human colorectal cancer development
is not yet clear. Studies on the correlations between serum
leptin levels and cancer produced contradictory results [32–35].
However, we found significant leptin overexpression in
colorectal cancer biopsies, while relatively low levels of the
hormone were identified in normal colorectal epithelium and
colorectal adenomas [30]. Thus, it possible that local, rather
than endocrine, leptin could exert a crucial role in cancer
development and progression.
Here, we provided evidence for statistically significant
coexpression of leptin and ObR, indicating that leptin might
activate colorectal cancer cells through an autocrine
mechanism, similar to that observed in breast and
endometrial cancers [8–20]. In addition, we found a positive
correlation between leptin and HIF-1a as well as ObR and
HIF-1a, which indicates that the expression of the leptin
Annals of Oncology symposium article
Volume 18 | Supplement 6 | June 2007 doi:10.1093/annonc/mdm238 | vi117
system could, at least in part, be HIF-1a mediated.
Interestingly, significant relationships between leptin and
HIF-1a and ObR and HIF-1a were seen in more advanced
subgroups of cancer cases, which could indicate the
involvement of the leptin system in some steps of colorectal
cancer progression related to hypoxia. On the other hand,
lack of correlations among studied proteins in poorly
differentiated tumors might indicate leptin-independent
growth during the process of dedifferentiation. We noted
concomitant expression of the leptin system and HIF-1a in
endometrial cancer, but the markers were not correlated with
histological grade, and extent of tumor growth (pT) [13].
In conclusion, our current and previous observations as
well as the results from other laboratories indicate that
HIF-1a may play a role in the progression of various
human malignancies, including colorectal cancer via
up-regulation of the leptin system.
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